Breast Cancer Therapeutics in Major Developed Market Growth & Research Report 2021 Radiant Insights, Inc
Summary Breast cancer, a malignant neoplasm, is the second most common cancer and the most common cancer in women worldwide, accounting for 16% of all female cancers, making the disease exceedingly prevalent. The number of women diagnosed with breast cancer has increased over the past few decades, but the number of deaths has declined due to earlier diagnosis and better treatment options. Breast cancer treatment has been revolutionized in the past four decades, especially with increasing usage of targeted therapies. The marketed products landscape comprises a wide range of treatment options, including hormonal therapies, chemotherapies, combination therapies, and targeted therapies. Nevertheless, significant unmet need remains for products that can improve overall survival rate, time to disease progression, and overall response. Read Complete Report With TOC @ http://www.radiantinsights.com/research/breast-cancer-therapeutics-in-major-developed-markets Scope The current breast cancer market contains novel products, including Perjeta, a targeted therapy; Kadcyla, a human antibody-drug conjugate; and Halaven, a novel chemotherapeutic agent. - What are the competitive advantages of the existing novel drugs? With over 700 active pipeline molecules, most of the investigational drug candidates are being evaluated for the first-line or second-line treatment of advanced-stage breast cancer, featuring new combination therapies, targeted therapies, and promising immunotherapies, as well as chemotherapy drug candidates. - Which classes of novel drugs are most prominent within the pipeline? - Is there strong potential for the pipeline to address unmet needs within the breast cancer market? Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II (41%), with the overall attrition rate for breast cancer in development being 61%. - How do failure rates vary by product stage of development, molecule type, and mechanism of action? - How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development? Over the 2014–2021 forecast period, the breast cancer therapeutics market in the eight major markets is expected to increase in value at a CAGR of 7.3%, from $10.4 billion to over $17.2 billion.
Summary
Breast cancer, a malignant neoplasm, is the second most common cancer and the most common cancer in women worldwide, accounting for 16% of all female cancers, making the disease exceedingly prevalent. The number of women diagnosed with breast cancer has increased over the past few decades, but the number of deaths has declined due to earlier diagnosis and better treatment options.
Breast cancer treatment has been revolutionized in the past four decades, especially with increasing usage of targeted therapies. The marketed products landscape comprises a wide range of treatment options, including hormonal therapies, chemotherapies, combination therapies, and targeted therapies. Nevertheless, significant unmet need remains for products that can improve overall survival rate, time to disease progression, and overall response.
Read Complete Report With TOC @ http://www.radiantinsights.com/research/breast-cancer-therapeutics-in-major-developed-markets
Scope
The current breast cancer market contains novel products, including Perjeta, a targeted therapy; Kadcyla, a human antibody-drug conjugate; and Halaven, a novel chemotherapeutic agent.
- What are the competitive advantages of the existing novel drugs?
With over 700 active pipeline molecules, most of the investigational drug candidates are being evaluated for the first-line or second-line treatment of advanced-stage breast cancer, featuring new combination therapies, targeted therapies, and promising immunotherapies, as well as chemotherapy drug candidates.
- Which classes of novel drugs are most prominent within the pipeline?
- Is there strong potential for the pipeline to address unmet needs within the breast cancer market?
Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II (41%), with the overall attrition rate for breast cancer in development being 61%.
- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?
Over the 2014–2021 forecast period, the breast cancer therapeutics market in the eight major markets is expected to increase in value at a CAGR of 7.3%, from $10.4 billion to over $17.2 billion.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
3.1.3 Af<strong>in</strong>itor (everolimus) – Novartis 27<br />
3.1.4 Tykerb/ Tyverb (lapat<strong>in</strong>ib ditosylate monohydrate) – Novartis 28<br />
3.1.5 Ibrance (palbociclib) – Pfizer 29<br />
3.1.6 Ixempra (ixabepilone) – Bristol-Myers Squibb 29<br />
3.1.7 Halaven (eribul<strong>in</strong> mesylate) – Eisai 30<br />
3.1.8 Avast<strong>in</strong> (bevacizumab) – Genentech 31<br />
3.1.9 Kadcyla (ado-trastuzumab emtans<strong>in</strong>e) – Genentech 31<br />
3.1.10 <strong>Market</strong>ed Products Heatmap 32<br />
3.1.11 Measur<strong>in</strong>g the Effectiveness of Treatment 38<br />
3.2 Conclusion 39<br />
Read Complete <strong>Report</strong> With TOC @ http://www.radiant<strong>in</strong>sights.com/research/breast-cancertherapeutics-<strong>in</strong>-major-developed-markets<br />
4 Pipel<strong>in</strong>e Products 40<br />
4.1 Pipel<strong>in</strong>e Products 40<br />
4.1.1 Overall Pipel<strong>in</strong>e 40<br />
4.1.2 Pipel<strong>in</strong>e by Molecular Target 41<br />
4.2 Cl<strong>in</strong>ical Trials 44<br />
4.2.1 Failure Rate 44<br />
4.2.2 Patient Enrollment and Cl<strong>in</strong>ical Trial Size 46<br />
4.2.3 Duration 50<br />
4.3 Competitive Cl<strong>in</strong>ical Trials Metrics Analysis 52<br />
5 Promis<strong>in</strong>g Drug Candidates <strong>in</strong> Pipel<strong>in</strong>e 54<br />
5.1 Abemaciclib – Eli Lily 54<br />
5.1.1 Abemaciclib Forecast 54
Change language